This is for informational purposes only. For medical advice or diagnosis, consult a professional.
Febuvent 40 mg Tablets – Pack of 30
Febuvent 40 mg is a potent, non-purine selective inhibitor of xanthine oxidase (NP-SIXO) indicated for the chronic management of hyperuricemia in patients with gout. By strategically inhibiting the xanthine oxidase enzyme, this pharmacological agent reduces the biochemical synthesis of uric acid, thereby lowering serum urate levels and preventing the crystallization of monosodium urate in articular tissues. It provides a targeted therapeutic approach for patients requiring intensive urate-lowering therapy (ULT).
Key Features
- Targeted Enzyme Inhibition: Selectively blocks the xanthine oxidase enzyme responsible for converting hypoxanthine and xanthine into uric acid.
- Serum Urate Regulation: Clinically formulated to achieve and maintain serum uric acid levels below the therapeutic threshold of 6 mg/dL.
- Superior Pharmacokinetic Profile: Offers an alternative for patients who are intolerant to allopurinol or require a non-purine based metabolic pathway.
- Prophylactic Efficacy: Regular administration aids in the significant reduction of gout flares and the dissolution of existing tophi over prolonged treatment periods.
- Standardized Dosing: Each 40 mg tablet provides a precise, bioavailable dose designed for once-daily systemic maintenance.
Recommended Usage
For oral administration as directed by a healthcare professional. The standard adult dose is one 40 mg tablet once daily, regardless of food intake. Febuvent is intended for chronic management and should not be initiated during an acute gout attack. Serum uric acid levels should be monitored at 2 to 4-week intervals following treatment initiation to assess efficacy. Ensure adequate systemic hydration during therapy to support renal excretion.